OVID
Ovid Therapeutics Inc.NASDAQHealthcare$2.20+1.85%ClosedMarket Cap: $332.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.44
P/S
47.90
EV/EBITDA
-8.31
DCF Value
$-0.92
FCF Yield
-11.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.2%
Operating Margin
-585.2%
Net Margin
-240.1%
ROE
-24.0%
ROA
-11.5%
ROIC
-29.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $718.0K | 93.9% | $-12.3M | $9.7M | $0.12 | — |
| FY 2025 | $7.3M | 95.9% | $-42.4M | $-17.4M | $-0.24 | — |
| Q3 2025 | $132.0K | 87.1% | $-12.5M | $-12.2M | $-0.17 | — |
| Q2 2025 | $6.3M | 100.0% | $-5.1M | $-4.7M | $-0.07 | — |
| Q1 2025 | $130.0K | 100.0% | $-12.6M | $-10.2M | $-0.14 | — |
| Q4 2024 | $76.0K | 100.0% | $-10.7M | $-9.3M | $-0.13 | — |
| FY 2024 | $566.0K | 100.0% | $-61.9M | $-26.4M | $-0.37 | — |
| Q3 2024 | $173.0K | 100.0% | $-13.2M | $-14.0M | $-0.20 | — |
| Q2 2024 | $169.0K | 100.0% | $-20.5M | $8.5M | $0.12 | — |
| Q1 2024 | $148.0K | 100.0% | $-17.4M | $-11.7M | $-0.17 | — |
| Q4 2023 | $142.0K | 100.0% | $-18.2M | $-15.3M | $-0.22 | — |
| FY 2023 | $392.0K | 100.0% | $-59.3M | $-52.3M | $-0.74 | — |